Clinical stage biopharmaceutical company Poxel SA (Euronext Paris:POXEL) announced on Monday that net sales of TWYMEEG in Japan surpassed JPY5bn in its Japanese partner Sumitomo Pharma Co Ltd's (TYO:4506) fiscal year 2024.
This achievement triggers a 10% royalty on all TWYMEEG net sales and a one-time JPY500m sales-based payment for Poxel.
These revenues will be used to repay the bond issue with OrbiMed and partially repay debt to IPF Partners.
Poxel expects escalating double-digit royalties and additional sales-based payments upon the achievement of future sales thresholds.
(USD1=JPY155.52)
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government